Exhibit 99.1 Privia Health Reports First Quarter 2024 Financial Results – Practice Collections +7.4% compared to 1Q’23 – Implemented Providers +17.3% compared to 1Q’23 – Company Reiterated Full Year 2024 Guidance ARLINGTON, VA – May 9, 2024 – Privia Health Group, Inc. (Nasdaq: PRVA) today announced financial results for the first quarter ended March 31, 2024. For the Three Months Ended March 31, ($ in millions, except per share amounts) 2024 2023 Change (%) Total revenue $ 415.2 $ 386.3 7.5 % Gross profit $ ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 10-K _______________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40365 _________________________ Privia Health Group, Inc. (Exact ...

Privia Health Group, Inc. (NASDAQ:PRVA) Q4 2023 Earnings Conference Call February 27, 2024 8:00 AM ET Company Participants Robert Borchert - SVP, Investor & Corporate Communications Parth Mehrotra - President and CEO David Mountcastle - CFO Conference Call Participants Joshua Raskin - Nephron Research Unidentified Analyst - Jefferies Lisa Gill - J.P. Morgan Jack Senft - William Blair Sameer Patel - Evercore ISI David Larsen - BTIG Jessica Tassan - Piper Sandler Gary Taylor - TD Cowen Richard Close - Canacco ...

4th Quarter 2023 Results February 27, 2024 Parth Mehrotra – Chief Executive Officer David Mountcastle – Chief Financial Officer 11 Disclaimer Forward-Looking Statements This presentation contains forward-looking statements that express the Company’s opinions, expectations, beliefs, plans, objectives, assumptions or projectionsregardingfutureeventsorfutureresultsthatinclude,butarenotlimitedto: 2024financialguidanceandotherprojectionsandforecasts.These forward-looking statements involve a number of risks, unc ...

Exhibit 99.1 Privia Health Reports Fourth Quarter and Full-Year 2023 Financial Results – Achieved All 2023 Operating and Financial Guidance Metrics – Implemented Providers +19.4% compared to Year-End 2022 – Introduces Full-Year 2024 Guidance – Proactive Steps to Limit Downside Risk Arrangements in Current Medicare Advantage Environment for More Favorable Contract Structures and Margin Contribution ARLINGTON, VA – February 27, 2024 – Privia Health Group, Inc. (Nasdaq: PRVA) today announced financial and oper ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 10-Q _______________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40365 _________________________ Privia Health Gr ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 10-Q _______________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40365 _________________________ Privia Health Group, ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 10-Q _______________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40365 _________________________ Privia Health Group, ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 10-K _______________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40365 _________________________ Privia Health Group, Inc. (Exact ...